Systems biology of cancer: Entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence"

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 403-421

  Tarabichi, M ^a   Antoniou, A ^a   Saiselet, M ^a   Pita, J M ^a,d   Andry, G ^c   Dumont, J E ^a   Detours, V ^a   Maenhaut, C ^a,b  

^a IRIBHM   (Belgium)

^b WELBIO ^*  (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Cancer; Emergence; Entropy; Noise; Systems biology

Indexed keywords

MICRORNA;

AGING; ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL INTERACTION; CELL METABOLISM; CELL TRANSFORMATION; DNA DAMAGE; ENTROPY; EPIGENETICS; HUMAN; HYPOXIA; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; SYSTEMS BIOLOGY; TUMOR CELL; TUMOR INVASION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; SYSTEMS BIOLOGY;

EID: 84890315312     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9431-y     Document Type: Article

References (252)

1. Ashworth, A., Lord, C. J., & Reis-Filho, J. S. (2011). Genetic interactions in cancer progression and treatment. Cell, 145, 30-38.
2. Teschendorff, A. E., & Severini, S. (2010). BMC.Syst.Biol, 4, 104.
3. Kayser, K., Kayser, G., Eichhorn, S., Biechele, U., Altiner, M., Kaltner, H., et al. (1998). Association of prognosis in surgically treated lung cancer patients with cytometric, histometric and ligand histochemical properties: With an emphasis on structural entropy. Analytical and Quantitative Cytology and Histology, 20, 313-320.
4. Agrell, U. (1986). Draft of a general stochastic theory of cancer and its possible experimental verification with monoclonal multiplication of repairing and immunological systems. Medical Hypotheses, 20, 261-270.
5. West, J., Bianconi, G., Severini, S., & Teschendorff, A. E. (2012). Differential network entropy reveals cancer system hallmarks. Sci. Rep., 2, 802.
6. Berretta, R., & Moscato, P. (2010). Cancer biomarker discovery: The entropic hallmark. PLoS One, 5, e12262.
7. van Wieringen, W. N., & van der Vaart, A. W. (2011). Statistical analysis of the cancer cell's molecular entropy using high-throughput data. Bioinformatics, 27.
8. Dumont, J. E., Dremier, S., Pirson, I., & Maenhaut, C. (2002). Cross signaling, cell specificity, and physiology. American Journal of Physiology. Cell Physiology, 283, C2-28.
9. Riggs, J. E. (1994). Carcinogenesis, genetic instability and genomic entropy: Insight derived from malignant brain tumor age specific mortality rate dynamics. Journal of Theoretical Biology, 170, 331-338.
10. Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome. Nature, 458, 719-724.
11. Foulkes, W. D. (2008). Inherited susceptibility to common cancers. The New England Journal of Medicine, 359, 2143-2153.
12. Kretzschmar, K., & Watt, F. M. (2012). Lineage tracing. Cell, 148, 33-45.
13. Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., et al. (2012). The origin and evolution of mutations in acute myeloid leukemia. Cell, 150, 264-278.
14. Rausch, T., Jones, D. T., Zapatka, M., Stutz, A. M., Zichner, T., Weischenfeldt, J., et al. (2012). Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell, 148, 59-71.
15. Maher, C. A., & Wilson, R. K. (2012). Chromothripsis and human disease: Piecing together the shattering process. Cell, 148, 29-32.
16. Holland, A. J., & Cleveland, D. W. (2012). Chromoanagenesis and cancer: Mechanisms and consequences of localized, complex chromosomal rearrangements. Nature Medicine, 18, 1630-1638.
17. Setlur, S. R., & Lee, C. (2012). Tumor archaeology reveals that mutations love company. Cell, 149, 959-961.
18. Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., et al. (2012). The life history of 21 breast cancers. Cell, 149, 994-1007.
19. Garcia-Cao, I., Song, M. S., Hobbs, R. M., Laurent, G., Giorgi, C., de Boer, V. C., et al. (2012). Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell, 149, 49-62.
20. Wang, Q., & Greene, M. I. (2008). Mechanisms of resistance to ErbB-targeted cancer therapeutics. The Journal of Clinical Investigation, 118, 2389-2392.
21. Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., et al. (2010). Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 468, 829-833.
22. Sotillo, R., Schvartzman, J. M., Socci, N. D., & Benezra, R. (2010). Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature, 464, 436-440.
23. Hayden, E. J., Ferrada, E., & Wagner, A. (2011). Cryptic genetic variation promotes rapid evolutionary adaptation in an RNA enzyme. Nature, 474, 92-95.
24. Jacobs, K. B., Yeager, M., Zhou, W., Wacholder, S., Wang, Z., Rodriguez-Santiago, B., et al. (2012). Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 44, 651-658.
25. Laurie, C. C., Laurie, C. A., Rice, K., Doheny, K. F., Zelnick, L. R., McHugh, C. P., et al. (2012). Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nature Genetics, 44, 642-650.
26. Jallepalli, P. V., & Pellman, D. (2007). Cell biology. Aneuploidy in the balance. Science, 317, 904-905.
27. Sheltzer, J. M., & Amon, A. (2011). The aneuploidy paradox: Costs and benefits of an incorrect karyotype. Trends in Genetics, 27, 446-453.
28. Pfau, S. J., & Amon, A. (2012). Chromosomal instability and aneuploidy in cancer: From yeast to man. EMBO Reports, 13, 515-527.
29. Kolodner, R. D., Cleveland, D. W., & Putnam, C. D. (2011). Cancer. Aneuploidy drives a mutator phenotype in cancer. Science, 333, 942-943.
30. Kim, N., & Jinks-Robertson, S. (2012). Transcription as a source of genome instability. Nature Reviews Genetics, 13, 204-214.
31. Engellau, J., Samuelsson, V., Anderson, H., Bjerkehagen, B., Rissler, P., Sundby-Hall, K., et al. (2007). Identification of low-risk tumours in histological high-grade soft tissue sarcomas. European Journal of Cancer, 43, 1927-1934.
32. Venet, D., Dumont, J. E., & Detours, V. (2011). Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Computational Biology, 7, e1002240.
33. Dai, C., Dai, S., & Cao, J. (2012). Proteotoxic stress of cancer: Implication of the heat-shock response in oncogenesis. J Cell Physiol, 227, 2982-2987.
34. Deplancke, B., & Verstrepen, K. J. (2012). Genetics. Variable outcome of mutations. Science, 335, 44-45.
35. Chen, G., Bradford, W. D., Seidel, C. W., & Li, R. (2012). Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature, 482, 246-250.
36. Alimonti, A., Carracedo, A., Clohessy, J. G., Trotman, L. C., Nardella, C., Egia, A., et al. (2010). Subtle variations in PTEN dose determine cancer susceptibility. Nature Genetics, 42, 454-458.
37. Frum, R. A., Khondker, Z. S., & Kaufman, D. G. (2009). Temporal differences in DNA replication during the S phase using single fiber analysis of normal human fibroblasts and glioblastoma T98G cells. Cell Cycle, 8, 3133-3148.
38. Brulliard, M., Lorphelin, D., Collignon, O., Lorphelin, W., Thouvenot, B., Gothie, E., et al. (2007). Nonrandom variations in human cancer ESTs indicate that mRNA heterogeneity increases during carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104, 7522-7527.
39. Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472, 90-94.
40. Ogier, V., Brulliard, M., Thouvenot, B., Battais, F., Notet, V., Richard, C., et al. (2009). Decoding aberrant cancer mRNA: Novel path toward diagnosis and understanding non small cell lung cancer heterogeneity. Poster presented at the 100th Annual Meeting 2009, American Association for Cancer Research, Denver, CO. Abstract retrieved from http://www.aacr.org/home/scientists/meetings - workshops/aacr-annual-meeting-2013/previous-annual-meetings/annual-meeting-2009. aspx (Program: pp 411-460: Wednesday, April 22, p 33, poster 9).
41. Kimura, T., Van Keymeulen, A., Golstein, J., Fusco, A., Dumont, J. E., & Roger, P. P. (2001). Regulation of thyroid cell proliferation by TSH and other factors: A critical evaluation of in vitro models. Endocrine Reviews, 22, 631-656.
42. Dumont, J. E., Pecasse, F., & Maenhaut, C. (2001). Crosstalk and specificity in signalling. Are we crosstalking ourselves into general confusion? Cellular Signalling, 13, 457-463.
43. Eldar, A., & Elowitz, M. B. (2010). Functional roles for noise in genetic circuits. Nature, 467, 167-173.
44. Pujadas, E., & Feinberg, A. P. (2012). Regulated noise in the epigenetic landscape of development and disease. Cell, 148, 1123-1131.
45. Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., et al. (2011). Increased methylation variation in epigenetic domains across cancer types. Nature Genetics, 43, 768-775.
46. Babu, M. M. (2010). Early career research award lecture. Structure, evolution and dynamics of transcriptional regulatory networks. Biochemical Society Transactions, 38, 1155-1178.
47. Pelkmans, L. (2012). Cell biology. Using cell-to-cell variability - A new era in molecular biology. Science, 336, 425-426.
48. Pickrell, J. K., Pai, A. A., Gilad, Y., & Pritchard, J. K. (2010). Noisy splicing drives mRNA isoform diversity in human cells. PLoS Genetics, 6, e1001236.
49. Neve, P., & Dumont, J. E. (1970). Time sequence of ultrastructural changes in the stimulated dog thyroid. Zeitschrift für Zellforschung und mikroskopische Anatomie, 103, 61-74.
50. Tay, S., Hughey, J. J., Lee, T. K., Lipniacki, T., Quake, S. R., & Covert, M. W. (2010). Single-cell NF-kappaB dynamics reveal digital activation and analogue information processing. Nature, 466, 267-271.
51. Rovira-Graells, N., Gupta, A. P., Planet, E., Crowley, V. M., Mok, S., Ribas, d. P., et al. (2012). Transcriptional variation in the malaria parasite Plasmodium falciparum. Genome Research, 22, 925-938.
52. Maamar, H., Raj, A., & Dubnau, D. (2007). Noise in gene expression determines cell fate in Bacillus subtilis. Science, 317, 526-529.
53. Avery, S. V. (2006). Microbial cell individuality and the underlying sources of heterogeneity. Nature Reviews Microbiology, 4, 577-587.
54. Sigal, A., Milo, R., Cohen, A., Geva-Zatorsky, N., Klein, Y., Liron, Y., et al. (2006). Variability and memory of protein levels in human cells. Nature, 444, 643-646.
55. Snijder, B., & Pelkmans, L. (2011). Origins of regulated cell-to-cell variability. Nature Reviews Molecular Cell Biology, 12, 119-125.
56. Masel, J., & Siegal, M. L. (2009). Robustness: Mechanisms and consequences. Trends in Genetics, 25, 395-403.
57. Lestas, I., Vinnicombe, G., & Paulsson, J. (2010). Fundamental limits on the suppression of molecular fluctuations. Nature, 467, 174-178.
58. Hahn, W. C., & Weinberg, R. A. (2002). Modelling the molecular circuitry of cancer. Nature Reviews. Cancer, 2, 331-341.
59. Zwang, Y., Oren, M., & Yarden, Y. (2012). Consistency test of the cell cycle: Roles for p53 and EGR1. Cancer Research, 72, 1051-1054.
60. Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., et al. (2006). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 103, 57-62.
61. Berezikov, E. (2011). Evolution of microRNA diversity and regulation in animals. Nature Reviews Genetics, 12, 846-860.
62. Ebert, M. S., & Sharp, P. A. (2012). Roles for microRNAs in conferring robustness to biological processes. Cell, 149, 515-524.
63. Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The impact of microRNAs on protein output. Nature, 455, 64-71.
64. Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 455, 58-63.
65. Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136, 215-233.
66. Alvarez-Saavedra, E., & Horvitz, H. R. (2010). Many families of C. elegans microRNAs are not essential for development or viability. Current Biology, 20, 367-373.
67. Rodriguez, W., Jin, L., Janssens, V., Pierreux, C., Hick, A. C., Urizar, E., et al. (2012). Deletion of the RNaseIII enzyme dicer in thyroid follicular cells causes hypothyroidism with signs of neoplastic alterations. PLoS One, 7, e29929.
68. Bueno, M. J., de Cedron, G., Laresgoiti, U., Fernandez-Piqueras, J., Zubiaga, A. M., & Malumbres, M. (2010). Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Molecular and Cellular Biology, 30, 2983-2995.
69. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704-714.
70. van Kouwenhove, M., Kedde, M., & Agami, R. (2011). MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature Reviews. Cancer, 11, 644-656.
71. Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., & Jacks, T. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics, 39, 673-677.
72. Esteller, M. (2011). Non-coding RNAs in human disease. Nature Reviews Genetics, 12, 861-874.
73. Voorhoeve, P. M. (2010). MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochimica et Biophysica Acta, 1805, 72-86.
74. Lopez-Serra, P., & Esteller, M. (2012). DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene, 31, 1609-1622.
75. Trang, P., Weidhaas, J. B., & Slack, F. J. (2008). MicroRNAs as potential cancer therapeutics. Oncogene, 27(2), S52-S57.
76. Maillot, G., Lacroix-Triki, M., Pierredon, S., Gratadou, L., Schmidt, S., Benes, V., et al. (2009). Widespread estrogen-dependent repression of microRNAs involved in breast tumor cell growth. Cancer Research, 69, 8332-8340.
77. Lujambio, A., & Lowe, S. W. (2012). The microcosmos of cancer. Nature, 482, 347-355.
78. Ravi, A., Gurtan, A. M., Kumar, M. S., Bhutkar, A., Chin, C., Lu, V., et al. (2012). Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. Cancer Cell, 21, 848-855.
79. Vinuela, A., Snoek, L. B., Riksen, J. A., & Kammenga, J. E. (2010). Genome-wide gene expression regulation as a function of genotype and age in C. elegans. Genome Research, 20, 929-937.
80. Diderich, K., Alanazi, M., & Hoeijmakers, J. H. (2011). Premature aging and cancer in nucleotide excision repair-disorders. DNA Repair (Amst), 10, 772-780.
81. de Magalhaes, J. P., Curado, J., & Church, G. M. (2009). Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics, 25, 875-881.
82. Lushnikova, T., Bouska, A., Odvody, J., Dupont, W. D., & Eischen, C. M. (2011). Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression. Oncogene, 30, 4622-4631.
83. Michod, R. E. (2007). Evolution of individuality during the transition from unicellular to multicellular life. Proceedings of the National Academy of Sciences of the United States of America, 104(1), 8613-8618.
84. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646-674.
85. Srivastava, M., Simakov, O., Chapman, J., Fahey, B., Gauthier, M. E., Mitros, T., et al. (2010). The Amphimedon queenslandica genome and the evolution of animal complexity. Nature, 466, 720-726.
86. Lugini, L., Matarrese, P., Tinari, A., Lozupone, F., Federici, C., Iessi, E., et al. (2006). Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Research, 66, 3629-3638.
87. Overholtzer, M., Mailleux, A. A., Mouneimne, G., Normand, G., Schnitt, S. J., King, R. W., et al. (2007). A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell, 131, 966-979.
88. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57-70.
89. Kuppers, M., Faust, D., Linz, B., & Dietrich, C. (2011). Regulation of ERK1/2 activity upon contact inhibition in fibroblasts. Biochemical and Biophysical Research Communications, 406, 483-487.
90. Baylin, S. B., & Jones, P. A. (2011). A decade of exploring the cancer epigenome - Biological and translational implications. Nature Reviews. Cancer, 11, 726-734.
91. Rubin, H. (2011). Fields and field cancerization: The preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. BioEssays, 33, 224-231.
92. Kamarajugadda, S., Stemboroski, L., Cai, Q., Simpson, N. E., Nayak, S., Tan, M., et al. (2012). Glucose oxidation modulates anoikis and tumor metastasis. Molecular and Cellular Biology, 32, 1893-1907.
93. Bissell, M. J., & Hines, W. C. (2011). Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine, 17, 320-329.
94. Rubin, H. (2008). Cell-cell contact interactions conditionally determine suppression and selection of the neoplastic phenotype. Proceedings of the National Academy of Sciences of the United States of America, 105, 6215-6221.
95. Gordon, D. J., Resio, B., & Pellman, D. (2012). Causes and consequences of aneuploidy in cancer. Nature Reviews Genetics, 13, 189-203.
96. Leung, C. T., & Brugge, J. S. (2012). Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature, 482, 410-413.
97. Mesnil, M., Crespin, S., Avanzo, J. L., & Zaidan-Dagli, M. L. (2005). Defective gap junctional intercellular communication in the carcinogenic process. Biochimica et Biophysica Acta, 1719, 125-145.
98. Matter, K., & Balda, M. S. (2007). Epithelial tight junctions, gene expression and nucleo-junctional interplay. Journal of Cell Science, 120, 1505-1511.
99. Saadat, I., Higashi, H., Obuse, C., Umeda, M., Murata-Kamiya, N., Saito, Y., et al. (2007). Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature, 447, 330-333.
100. Radisky, D. C., & Bissell, M. J. (2006). Matrix metalloproteinase- induced genomic instability. Current Opinion in Genetics and Development, 16, 45-50.
101. McCaffrey, L. M., & Macara, I. G. (2011). Epithelial organization, cell polarity and tumorigenesis. Trends in Cell Biology, 21, 727-735.
102. Driessens, G., Beck, B., Caauwe, A., Simons, B. D., & Blanpain, C. (2012). Defining the mode of tumour growth by clonal analysis. Nature, 488, 527-530.
103. Tomas, G., Tarabichi, M., Gacquer, D., Hebrant, A., Dom, G., Dumont, J. E., et al. (2012). A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic. Oncogene, 31, 4490-4498.
104. Harding, C., Pompei, F., & Wilson, R. (2012). Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer, 118, 1371-1386.
105. de Beco, S., Ziosi, M., & Johnston, L. A. (2012). New frontiers in cell competition. Developmental Dynamics, 241, 831-841.
106. Johnston, L. A. (2009). Competitive interactions between cells: Death, growth, and geography. Science, 324, 1679-1682.
107. Marinari, E., Mehonic, A., Curran, S., Gale, J., Duke, T., & Baum, B. (2012). Live-cell delamination counterbalances epithelial growth to limit tissue overcrowding. Nature, 484, 542-545.
108. Eisenhoffer, G. T., Loftus, P. D., Yoshigi, M., Otsuna, H., Chien, C. B., Morcos, P. A., et al. (2012). Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia. Nature, 484, 546-549.
109. Portela, M., Casas-Tinto, S., Rhiner, C., Lopez-Gay, J. M., Dominguez, O., Soldini, D., et al. (2010). Drosophila SPARC is a self-protective signal expressed by loser cells during cell competition. Developmental Cell, 19, 562-573.
110. Franklin, W. A., Gazdar, A. F., Haney, J., Wistuba, I. I., La Rosa, F. G., Kennedy, T., et al. (1997). Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. The Journal of Clinical Investigation, 100, 2133-2137.
111. Pearson, H. B., Perez-Mancera, P. A., Dow, L. E., Ryan, A., Tennstedt, P., Bogani, D., et al. (2011). SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. The Journal of Clinical Investigation, 121, 4257-4267.
112. Zhao, B., Tumaneng, K., & Guan, K. L. (2011). The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature Cell Biology, 13, 877-883.
113. Chen, X., Sun, H., Ren, S., Kim, C. V., Zhang, L., Zhou, S., et al. (2012). Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clinical and Translational Oncology, 14, 207-213.
114. Chen, C. L., Schroeder, M. C., Kango-Singh, M., Tao, C., & Halder, G. (2012). Tumor suppression by cell competition through regulation of the Hippo pathway. Proceedings of the National Academy of Sciences of the United States of America, 109, 484-489.
115. Tumaneng, K., Russell, R. C., & Guan, K. L. (2012). Organ size control by Hippo and TOR pathways. Current Biology, 22, R368-R379.
116. Farber, E. (1996). The step-by-step development of epithelial cancer: From phenotype to genotype. Advances in Cancer Research, 70, 21-48.
117. Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481, 306-313.
118. Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., et al. (2012). Mutational processes molding the genomes of 21 breast cancers. Cell, 149, 979-993.
119. Ma, Q. C., Ennis, C. A., & Aparicio, S. (2012). Opening Pandora's Box - The new biology of driver mutations and clonal evolution in cancer as revealed by next generation sequencing. Current Opinion in Genetics and Development, 22, 3-9.
120. Sprouffske, K., Merlo, L. M., Gerrish, P. J., Maley, C. C., & Sniegowski, P. D. (2012). Cancer in light of experimental evolution. Current Biology, 22, R762-R771.
121. Loeb, L. A. (2011). Human cancers express mutator phenotypes: Origin, consequences and targeting. Nature Reviews. Cancer, 11, 450-457.
122. Bartkova, J., Horejsi, Z., Koed, K., Kramer, A., Tort, F., Zieger, K., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-870.
123. Close, P., East, P., Dirac-Svejstrup, A. B., Hartmann, H., Heron, M., Maslen, S., et al. (2012). DBIRD complex integrates alternative mRNA splicing with RNA polymerase II transcript elongation. Nature, 484, 386-389.
124. Solimini, N. L., Luo, J., & Elledge, S. J. (2007). Non-oncogene addiction and the stress phenotype of cancer cells. Cell, 130, 986-988.
125. Yates, L. R., & Campbell, P. J. (2012). Evolution of the cancer genome. Nature Reviews Genetics, 13, 795-806.
126. Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 481, 506-510.
127. Bhatia, S., Frangioni, J. V., Hoffman, R. M., Iafrate, A. J., & Polyak, K. (2012). The challenges posed by cancer heterogeneity. Nature Biotechnology, 30, 604-610.
128. Vincent, A., & Van, S. I. (2012). On the epigenetic origin of cancer stem cells. Biochimica et Biophysica Acta, 1826, 83-88.
129. Akhtar-Zaidi, B., Cowper-Sal-lari, R., Corradin, O., Saiakhova, A., Bartels, C. F., Balasubramanian, D., et al. (2012). Epigenomic enhancer profiling defines a signature of colon cancer. Science, 336, 736-739.
130. Helman, E., Naxerova, K., & Kohane, I. S. (2012). DNA hypermethylation in lung cancer is targeted at differentiation-associated genes. Oncogene, 31, 1181-1188.
131. Holmberg, J., & Perlmann, T. (2012). Maintaining differentiated cellular identity. Nature Reviews Genetics, 13, 429-439.
132. Maenhaut, C., Dumont, J. E., Roger, P. P., & van Staveren, W. C. (2010). Cancer stem cells: A reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis, 31, 149-158.
133. Swanton, C. (2012). Intratumor heterogeneity: Evolution through space and time. Cancer Research, 72, 4875-4882.
134. Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine, 366, 883-892.
135. Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., et al. (2012). Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell, 148, 886-895.
136. Li, Y., & Sea, X. X. L. (2012). Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. Giga Science, 1, 12.
137. Yea, L. (2012). Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. GigaScience, 1, 12.
138. Kohtz, C. (2011). Engaging students in an undergraduate research course. Nurse Educator, 36, 150-154.
139. Kaiser, J. (2011). Combining targeted drugs to stop resistant tumors. Science, 331, 1542-1545.
140. Frum, R. A., Khondker, Z. S., & Kaufman, D. G. (2009). Temporal differences in DNA replication during the S phase using single fiber analysis of normal human fibroblasts and glioblastoma T98G cells. Cell Cycle, 8, 3133-3148.
141. Bardelli, A., & Janne, P. A. (2012). The road to resistance: EGFR mutation and cetuximab. Nature Medicine, 18, 199-200.
142. Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. The New England Journal of Medicine, 366, 207-215.
143. Aziz, M. H., Shen, H., & Maki, C. G. (2011). Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene, 30, 4678-4686.
144. Shay, J. W., Reddel, R. R., & Wright, W. E. (2012). Cancer. Cancer and telomeres - An ALTernative to telomerase. Science, 336, 1388-1390.
145. Lambert, G., Estevez-Salmeron, L., Oh, S., Liao, D., Emerson, B. M., Tlsty, T. D., et al. (2011). An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nature Reviews. Cancer, 11, 375-382.
146. Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., et al. (2012). Passenger deletions generate therapeutic vulnerabilities in cancer. Nature, 488, 337-342.
147. Nijhawan, D., Zack, T. I., Ren, Y., Strickland, M. R., Lamothe, R., Schumacher, S. E., et al. (2012). Cancer vulnerabilities unveiled by genomic loss. Cell, 150, 842-854.
148. Khan, A. I., Dinh, D. M., Schneider, D., Lenski, R. E., & Cooper, T. F. (2011). Negative epistasis between beneficial mutations in an evolving bacterial population. Science, 332, 1193-1196.
149. Malaise, E. P., Chavaudra, N., & Tubiana, M. (1973). The relationship between growth rate, labelling index and histological type of human solid tumours. European Journal of Cancer, 9, 305-312.
150. Magee, J. A., Piskounova, E., & Morrison, S. J. (2012). Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell, 21, 283-296.
151. Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., et al. (2011). Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 146, 633-644.
152. Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews. Cancer, 3, 362-374.
153. Ferreira LM, Hebrant A, Dumont JE (2012): Metabolic reprogramming of the tumor. Oncogene.
154. Jones, R. G., & Thompson, C. B. (2009). Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes & Development, 23, 537-548.
155. Berardi, M. J., & Fantin, V. R. (2011). Survival of the fittest: Metabolic adaptations in cancer. Current Opinion in Genetics and Development, 21, 59-66.
156. Noh KH, Lee YH, Jeon JH, Kang TH, Mao CP, Wu TC, Kim TW (2012): Cancer vaccination drives Nanog-dependent evolution of tumor cells towards an immune-resistant and stem-like phenotype. Cancer Res 72:1717-1727
157. Barsoum, I. B., Hamilton, T. K., Li, X., Cotechini, T., Miles, E. A., Siemens, D. R., et al. (2011). Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: Role of nitric oxide. Cancer Research, 71, 7433-7441.
158. Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475, 226-230.
159. Hirschhaeuser, F., Sattler, U. G., & Mueller-Klieser, W. (2011). Lactate: A metabolic key player in cancer. Cancer Research, 71, 6921-6925.
160. De Bock, K., Cauwenberghs, S., & Carmeliet, P. (2011). Vessel abnormalization: Another hallmark of cancer? Molecular mechanisms and therapeutic implications. Current Opinion in Genetics and Development, 21, 73-79.
161. Bertos, N. R., & Park, M. (2011). Breast cancer - One term, many entities? The Journal of Clinical Investigation, 121, 3789-3796.
162. Polyak, K. (2011). Heterogeneity in breast cancer. The Journal of Clinical Investigation, 121, 3786-3788.
163. Dornan, D., & Settleman, J. (2011). Dissecting cancer heterogeneity. Nature Biotechnology, 29, 1095-1096.
164. Lotem, J., Netanely, D., Domany, E., & Sachs, L. (2005). Human cancers overexpress genes that are specific to a variety of normal human tissues. Proceedings of the National Academy of Sciences of the United States of America, 102, 18556-18561.
165. Dvorak, H. F. (1986). Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. The New England Journal of Medicine, 315, 1650-1659.
166. Jacobs, P. P., & Sackstein, R. (2011). CD44 and HCELL: Preventing hematogenous metastasis at step 1. FEBS Letters, 585, 3148-3158.
167. Colombo, S. L., Palacios-Callender, M., Frakich, N., De Leon, J., Schmitt, C. A., Boorn, L., et al. (2010). Anaphase-promoting complex/cyclosome-Cdh1 coordinates glycolysis and glutaminolysis with transition to S phase in human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 107, 18868-18873.
168. Almeida, A., Bolanos, J. P., & Moncada, S. (2010). E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 107, 738-741.
169. Liu, H., Radisky, D. C., Yang, D., Xu, R., Radisky, E. S., Bissell, M. J., et al. (2012). MYC suppresses cancer metastasis by direct transcriptional silencing of alpha(v) and beta(3) integrin subunits. Nature Cell Biology, 14, 567-574.
170. Nikolsky, Y., Sviridov, E., Yao, J., Dosymbekov, D., Ustyansky, V., Kaznacheev, V., et al. (2008). Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Research, 68, 9532-9540.
171. Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., et al. (2011). Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Medicine, 17, 1116-1120.
172. Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 487, 505-509.
173. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., et al. (2012). Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 489, 155-159.
174. Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., et al. (2012). Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 486, 532-536.
175. Creixell, P., Schoof, E. M., Erler, J. T., & Linding, R. (2012). Navigating cancer network attractors for tumor-specific therapy. Nature Biotechnology, 30, 842-848.
176. Celia-Terrassa, T., Meca-Cortes, O., Mateo, F., de Paz, A. M., Rubio, N., Arnal-Estape, A., et al. (2012). Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. The Journal of Clinical Investigation, 122, 1849-1868.
177. Friedl, P., & Alexander, S. (2011). Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell, 147, 992-1009.
178. The Cancer Genome Atlas Network. Gehlenborg NKRea. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330-337.
179. Koboldt DC, McLellan MD, Schimdt H, Cancer Genome Atlas Network (2012): Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
180. Christophe-Hobertus, C., Lefort, A., Libert, F., & Christophe, D. (2012). Functional inactivation of thyroid transcription factor-1 in PCCl3 thyroid cells. Molecular and Cellular Endocrinology, 358, 36-45.
181. Floor, S., van Staveren, W. C., Larsimont, D., Dumont, J. E., & Maenhaut, C. (2011). Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: Distinct, overlapping or same populations. Oncogene, 30, 4609-4621.
182. Lawlor, E. R., Soucek, L., Brown-Swigart, L., Shchors, K., Bialucha, C. U., & Evan, G. I. (2006). Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Research, 66, 4591-4601.
183. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., et al. (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 483, 100-103.
184. Sawyers, C. L. (2007). Cancer: mixing cocktails. Nature, 449, 993-996.
185. Kim, H. Y., Park, W. Y., Lee, K. E., Park, W. S., Chung, Y. S., Cho, S. J., et al. (2010). Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinoma. Journal of Cancer Research and Therapeutics, 6, 452-457.
186. Pazaitou-Panayiotou, K., Capezzone, M., & Pacini, F. (2007). Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid, 17, 1085-1092.
187. Peeper, D. S. (2011). Oncogene-induced senescence and melanoma: Where do we stand? Pigment Cell & Melanoma Research, 24, 1107-1111.
188. Rice, J. (2012). Metastasis: The rude awakening. Nature, 485, S55-S57.
189. Saab, R. (2011). Senescence and pre-malignancy: How do tumors progress? Seminars in Cancer Biology, 21, 385-391.
190. Melief, C. J. (2007). Cancer: Immune pact with the enemy. Nature, 450, 803-804.
191. Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nature Genetics, 33, 49-54.
192. Wu, M., Pastor-Pareja, J. C., & Xu, T. (2010). Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature, 463, 545-548.
193. Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 1109-1113.
194. Natoli, C., Ramazzotti, V., Nappi, O., Giacomini, P., Palmeri, S., Salvatore, M., et al. (2011). Unknown primary tumors. Biochimica et Biophysica Acta, 1816, 13-24.
195. Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: Molecular insights and evolving paradigms. Cell, 147, 275-292.
196. Brooks, S. A., Lomax-Browne, H. J., Carter, T. M., Kinch, C. E., & Hall, D. M. (2010). Molecular interactions in cancer cell metastasis. Acta Histochemica, 112, 3-25.
197. Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Research, 67, 3450-3460.
198. Carmeliet, P., & Jain, R. K. (2011). Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature Reviews. Drug Discovery, 10, 417-427.
199. Mierke, C. T. (2012). Endothelial cell's biomechanical properties are regulated by invasive cancer cells. Molecular BioSystems, 8, 1639-1649.
200. Podsypanina, K., Du, Y. C., Jechlinger, M., Beverly, L. J., Hambardzumyan, D., & Varmus, H. (2008). Seeding and propagation of untransformed mouse mammary cells in the lung. Science, 321, 1841-1844.
201. Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N., Morris, V. L., Chambers, A. F., et al. (1998). Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. The American Journal of Pathology, 153, 865-873.
202. Oskarsson, T., Acharyya, S., Zhang, X. H., Vanharanta, S., Tavazoie, S. F., Morris, P. G., et al. (2011). Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Medicine, 17, 867-874.
203. Tabaries, S., Dupuy, F., Dong, Z., Monast, A., Annis, M. G., Spicer, J., et al. (2012). Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Molecular and Cellular Biology, 32, 2979-2991.
204. Duda, D. G., Duyverman, A. M., Kohno, M., Snuderl, M., Steller, E. J., Fukumura, D., et al. (2010). Malignant cells facilitate lung metastasis by bringing their own soil. Proceedings of the National Academy of Sciences of the United States of America, 107, 21677-21682.
205. Friedl, P., Locker, J., Sahai, E., & Segall, J. E. (2012). Classifying collective cancer cell invasion. Nature Cell Biology, 14, 777-783.
206. Rebbeck, C. A., Leroi, A. M., & Burt, A. (2011). Mitochondrial capture by a transmissible cancer. Science, 331, 303.
207. Murchison, E. P. (2008). Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene, 27(2), S19-S30.
208. Murgia, C., Pritchard, J. K., Kim, S. Y., Fassati, A., & Weiss, R. A. (2006). Clonal origin and evolution of a transmissible cancer. Cell, 126, 477-487.
209. Belov, K. (2012). Contagious cancer: Lessons from the devil and the dog. BioEssays, 34, 285-292.
210. Isoda, T., Ford, A. M., Tomizawa, D., van Delft, F. W., De Castro, D. G., Mitsuiki, N., et al. (2009). Immunologically silent cancer clone transmission from mother to offspring. Proceedings of the National Academy of Sciences of the United States of America, 106, 17882-17885.
211. Sala-Torra, O., Hanna, C., Loken, M. R., Flowers, M. E., Maris, M., Ladne, P. A., et al. (2006). Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 12, 511-517.
212. Myron, K. H., McBride, M. A., Cherikh, W. S., Spain, P. C., Marks, W. H., & Roza, A. M. (2002). Transplant tumor registry: Donor related malignancies. Transplantation, 74, 358-362.
213. Bersini, H. (2010). Emergent phenomena belong only to biology. Synthese Springer Science-Business:Synthese. doi: 10.1007/s11229-010-9724-4.
214. Rorth, P. (2012). Fellow travellers: Emergent properties of collective cell migration. EMBO Reports, 13, 984-991.
215. Monod H, Lemaire C, Delavelle F, Saint-Saens M (1972): [Static work capacity in hypoxia]. J.Physiol (Paris) 65:Suppl 3:455A.
216. Brown, S. P., & Johnstone, R. A. (2001). Cooperation in the dark: Signalling and collective action in quorum-sensing bacteria. Proc. Biol. Sci., 268, 961-965.
217. Davidson, E. H. (2010). Emerging properties of animal gene regulatory networks. Nature, 468, 911-920.
218. Van der Veldt, A. A., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N., et al. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell, 21, 82-91.
219. Chang, Q., Jurisica, I., Do, T., & Hedley, D. W. (2011). Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Research, 71, 3110-3120.
220. Lee, S. L., Rouhi, P., Dahl, J. L., Zhang, D., Ji, H., Hauptmann, G., et al. (2009). Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proceedings of the National Academy of Sciences of the United States of America, 106, 19485-19490.
221. Hashimoto, O., Shimizu, K., Semba, S., Chiba, S., Ku, Y., Yokozaki, H., et al. (2011). Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1alpha-dependent manner in pancreatic cancer cells. Pathobiology, 78, 181-192.
222. Liu, S., Kumar, S. M., Martin, J. S., Yang, R., & Xu, X. (2011). Snail1 mediates hypoxia-induced melanoma progression. The American Journal of Pathology, 179, 3020-3031.
223. Keith, B., & Simon, M. C. (2007). Hypoxia-inducible factors, stem cells, and cancer. Cell, 129, 465-472.
224. Michieli, P. (2009). Hypoxia, angiogenesis and cancer therapy: To breathe or not to breathe? Cell Cycle, 8, 3291-3296.
225. Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfor, K., Rofstad, E. K., et al. (2000). High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research, 60, 916-921.
226. Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T., et al. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 468, 824-828.
227. Semenza, G. L. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene, 29, 625-634.
228. Alexander, S., & Friedl, P. (2012). Cancer invasion and resistance: Interconnected processes of disease progression and therapy failure. Trends in Molecular Medicine, 18, 13-26.
229. Soon, P. S., Kim, E., Pon, C. K., Gill, A. J., Moore, K., Spillane, A. J., et al. (2013). Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr Relat Cancer, 20, 1-12.
230. Goetz, J. G., Minguet, S., Navarro-Lerida, I., Lazcano, J. J., Samaniego, R., Calvo, E., et al. (2011). Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell, 146, 148-163.
231. Xue, Y., Lim, S., Yang, Y., Wang, Z., Jensen, L. D., Hedlund, E. M., et al. (2012). PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nature Medicine, 18, 100-110.
232. Roodhart, J. M., Daenen, L. G., Stigter, E. C., Prins, H. J., Gerrits, J., Houthuijzen, J. M., et al. (2011). Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell, 20, 370-383.
233. Zhang, M., Yang, J., Tao, L., Li, L., Ma, P., & Fawcett, J. P. (2012). Acarbose bioequivalence: Exploration of new pharmacodynamic parameters. The AAPS Journal, 14, 345-351.
234. Kosaka, N., Iguchi, H., Yoshioka, Y., Hagiwara, K., Takeshita, F., & Ochiya, T. (2012). Competitive interactions of cancer cells and normal cells via secretory microRNAs. The Journal of Biological Chemistry, 287, 1397-1405.
235. Rodier, F., & Campisi, J. (2011). Four faces of cellular senescence. The Journal of Cell Biology, 192, 547-556.
236. Mione, M., & Zon, L. I. (2012). Cancer and inflammation: An aspirin a day keeps the cancer at bay. Current Biology, 22, R522-R525.
237. DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F., & Jacks, T. (2012). Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 482, 405-409.
238. Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-1570.
239. Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., et al. (2012). Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Research, 72, 2746-2756.
240. Han, C. Z., & Ravichandran, K. S. (2011). Metabolic connections during apoptotic cell engulfment. Cell, 147, 1442-1445.
241. Kawada, K., & Taketo, M. M. (2011). Significance and mechanism of lymph node metastasis in cancer progression. Cancer Research, 71, 1214-1218.
242. Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F. F., et al. (2011). Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine, 17, 860-866.
243. Sonveaux, P., Brouet, A., Havaux, X., Gregoire, V., Dessy, C., Balligand, J. L., et al. (2003). Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: Implications for tumor radiotherapy. Cancer Research, 63, 1012-1019.
244. Kaplan, L. M., Fallon, J. A., Mun, E. C., Harvey, A. M., Kastrinakis, W. V., Johnson, E. Q., et al. (2005). Coding and reimbursement for weight loss surgery: Best practice recommendations. Obesity Research, 13, 290-300.
245. Werbowetski-Ogilvie, T. E., Schnerch, A., Rampalli, S., Mills, C. E., Lee, J. B., Hong, S. H., et al. (2011). Evidence for the transmission of neoplastic properties from transformed to normal human stem cells. Oncogene, 30, 4632-4644.
246. Sawyers, C. L. (2009). Shifting paradigms: The seeds of oncogene addiction. Nature Medicine, 15, 1158-1161.
247. Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M. L., et al. (2006). Generation of a functional mammary gland from a single stem cell. Nature, 439, 84-88.
248. Coclet, J., Foureau, F., Ketelbant, P., Galand, P., & Dumont, J. E. (1989). Cell population kinetics in dog and human adult thyroid. Clinical Endocrinology, 31, 655-665.
249. Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004). Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ, 328, 1519.
250. Glickman, M. S., & Sawyers, C. L. (2012). Converting cancer therapies into cures: Lessons from infectious diseases. Cell, 148, 1089-1098.
251. Basanta, D., Gatenby, R. A., & Anderson, A. R. (2012). Exploiting evolution to treat drug resistance: Combination therapy and the double bind. Molecular Pharmaceutics, 9, 914-921.
252. Bernards, R. (2012). A missing link in genotype-directed cancer therapy. Cell, 151, 465-468.